Match Document Document Title
US20140199350 CHIMERIC TOPICAL VACCINE FOR HAEMOPHILUS INFLUENZAE-INDUCED DISEASE  
Provided are delivery systems for topically administering a chimeric protein including the NTHi twitching pilus major subunit protein (PilA) presenting a portion of the NTHi OMP P5 protein. Also...
US20140314801 VACCINES AND METHODS TO TREAT LYME DISEASE IN DOGS  
The instant invention provides an immunogenic composition comprising an antigenic fragment of OspA protein of Borrelia burgdorferi and a chimeric protein containing antigenic fragments of...
US20120237536 COMBINATION VACCINES AGAINST RESPIRATORY TRACT DISEASES  
Influenza, pneumococcus and/or RSV vaccines are administered as a combination vaccine while retaining immunogenic efficacy. This combination simplifies immunisation against these two lower...
US20140056967 VACCINES AGAINST CHLAMYDIAL INFECTION  
The present invention relates to compositions comprising proteins or polynucleotides of Chlamydia sp., in particular combinations of proteins or polynucleotides encoding them, and methods for the...
US20110300206 VACCINES AGAINST CHLAMYDIAL INFECTION  
The present invention relates to compositions comprising proteins or polynucleotides of Chlamydia sp., in particular combinations of proteins or polynucleotides encoding them, and methods for the...
US20110189208 TB VACCINE  
The invention relates to a vaccine useful in therapy and prevention of mycobacterial infections.
US20140248273 VACCINE BASED ON STAPHYLOCOCCAL SUPERANTIGEN-LIKE 3 PROTEIN (SSL3)  
The present invention relates to the field of vaccinology, especially of vaccines against Staphylococcus aureus, for both human and veterinary application. In particular the invention relates to a...
US20130028926 BIOSYNTHETIC SYSTEM THAT PRODUCES IMMUNOGENIC POLYSACCHARIDES IN PROKARYOTIC CELLS  
The invention is directed to bioconjugate vaccines comprising N-glycosylated proteins. Further, the present invention is directed to a recombinant prokaryotic biosynthetic system comprising...
US20140161836 CARIOUS TOOTH VACCINE AND PREPARATION METHOD  
The present invention provides a vaccine composition for dental caries caused by S. mutans infection, where the vaccine composition comprises an antigen derived from a surface protein PAc of S....
US20120128709 EXPRESSION OF RECOMBINANT PROTEINS  
The invention provides auto-inducible systems for expressing recombinant proteins of interest which take advantage of elements of quorum sensing (QS) systems of certain bacteria. These systems can...
US20120195920 STAPHYLOCOCCUS AUREUS DIV1B FOR USE AS VACCINE  
The invention relates to an antigenic polypeptide referred to as DivlB and variants thereof, vaccines comprising said polypeptide and the use of the vaccine in protecting subjects from microbial...
US20150150959 BACTERIAL BIOFILM MATRIX AS A PLATFORM FOR PROTEIN DELIVERY  
Some aspects of this disclosure provide engineered exopolysaccharide-associated proteins, engineered bacteria expressing such proteins, and engineered biofilms comprising such proteins. Some...
US20130183331 IMMUNOGENIC PROTEINS FROM GENOME-DERIVED OUTER MEMBRANE OF LEPTOSPIRA AND COMPOSITIONS AND METHODS BASED THEREON  
Leptospira outer membrane proteins (OMPs) LP1454, LP1118, LP1939, MCEII, CADF-like1, CADF-like2, CADF-like3, Lp0022, Lp1499, Lp4337, Lp328 or L21 are provided. The OMPS can be used as tools for...
US20120100143 IMMUNOGENIC PROTEINS FROM GENOME-DERIVED OUTER MEMBRANE OF LEPTOSPIRA AND COMPOSITIONS AND METHODS BASED THEREON  
Leptospira outer membrane proteins (OMPs) LP1454, LP1118, LP1939, MCEII, CADF-like1, CADF-like2, CADF-like3, Lp0022, Lp1499, Lp4337, Lp328 or L21 are provided. The OMPS can be used as tools for...
US20110014225 CROSS-REACTIVE DETERMINANTS AND METHODS FOR THEIR IDENTIFICATION  
Compositions and methods for determining immunologically cross-reactive molecules comprising a cross-reactive antigenic determinant are provided, in particular for determining proteins comprising...
US20120263724 Escherichia coli o157:h7 proteins and uses thereof  
Immunogenic Escherichia coli O157:H7 (0157) proteins expressed during infection of a mammal, are described. In particular, 0157 proteins expressed specifically in vivo during human and cattle...
US20140141030 CHIMERIC OSPA GENES, PROTEINS AND METHODS OF USE THEREOF  
The invention relates to the development of chimeric OspA molecules for use in a new Lyme vaccine. More specifically, the chimeric OspA molecules comprise the proximal portion from one OspA...
US20140141029 CHIMERIC OSPA GENES, PROTEINS AND METHODS OF USE THEREOF  
The invention relates to the development of chimeric OspA molecules for use in a new Lyme vaccine. More specifically, the chimeric OspA molecules comprise the proximal portion from one OspA...
US20120020973 CHIMERIC OSPA GENES, PROTEINS, AND METHODS OF USE THEREOF  
The invention relates to the development of chimeric OspA molecules for use in a new Lyme vaccine. More specifically, the chimeric OspA molecules comprise the proximal portion from one OspA...
US20110293652 CHIMERIC OSPA GENES, PROTEINS, AND METHODS OF USE THEREOF  
The invention relates to the development of chimeric OspA molecules for use in a new Lyme vaccine. More specifically, the chimeric OspA molecules comprise the proximal portion from one OspA...
US20150140026 INTERACTION OF MORAXELLA CATARRHALIS WITH EPITHELIAL CELLS, EXTRACELLULAR MATRIX PROTEINS AND THE COMPLEMENT SYSTEM  
The present disclosure relates to surface proteins of Moraxella catarrhalis and their ability to interact with epithelial cells via cell-associated fibronectin and laminin, and also to their...
US20130129763 INTERACTION OF MORAXELLA CATARRHALIS WITH EPITHELIAL CELLS, EXTRACELLULAR MATRIX PROTEINS AND THE COMPLEMENT SYSTEM  
The present disclosure relates to surface proteins of Moraxella catarrhalis and their ability to interact with epithelial cells via cell-associated fibronectin and laminin, and also to their...
US20120148614 Interaction of Moraxella Catarrhalis with Epithelial Cells, Extracellular Matrix Proteins and the Complement System  
The present disclosure relates to surface proteins of Moraxella catarrhalis and their ability to interact with epithelial cells via cell-associated fibronectin and laminin, and also to their...
US20130236488 PORPHYROMONAS GINGIVALIS POLYPEPTIDES USEFUL IN THE PREVENTION OF PERIODONTAL DISEASE  
The invention is directed to vaccine compositions and methods based on P. gingivalis proteins identified to be regulated by haem availability that can be used in the prevention and treatment of...
US20140227314 Engineered Type IV Pilin of Clostridium difficile  
The present invention relates to engineered Clostridium difficile type IV pilin (tfp) genes, type IV pilin proteins which can serve as a diagnostic marker for identification of patients infected...
US20130337003 Engineered Type IV Pilin of Clostridium difficile  
The present invention relates to engineered Clostridium difficile type IV pilin (tfp) genes, type IV pilin proteins which can serve as a diagnostic marker for identification of patients infected...
US20120064105 Engineered Type IV Pilin of Clostridium difficile  
The present invention relates to engineered Clostridium difficile type IV pilin (tfp) genes, type IV pilin proteins which can serve as a diagnostic marker for identification of patients infected...
US20130004510 VACCINE  
Compositions and methods for the treatment or prevention of Gram-negative bacterial strain infection are provided herein. Methods for the manufacture of said compositions are also provided herein.
US20130280287 RECOMBINANT MYCOBACTERIUM AS VACCINE FOR USE IN HUMANS  
The invention relates to a recombinant vaccine providing protective immunity especially against tuberculosis in human subjects.
US20120135027 PROTEINS USED FOR THE DIAGNOSIS OF LYME BORRELIOSIS  
Chimera proteins including: (i) at least one sequence of a DbpA protein of a Borrelia species selected from B. afzelii, B. burgdorferi sensu stricto and B. garinii, and (ii) at least one sequence...
US20150024000 MULTIVALENT VACCINE PROTECTION FROM STAPHYLOCOCCUS AUREUS INFECTION  
Vaccine formulations effective against Staphylococcus aureus, including methicillin-resistant Staphylococcus aureus (MRSA) are disclosed, as well as methods of using the vaccine formulations in...
US20150079095 PREVENTON, TREATMENT AND DIAGNOSIS OF P. GINGIVALIS INFECTION  
The invention relates to generation and use of cellular and humoral responses for the prevention and treatment of P. gingivalis related conditions and diseases.
US20110280880 PREVENTION, TREATMENT AND DIAGNOSIS OF P.GINGIVALIS INFECTION  
The invention relates to generation and use of cellular and humoral responses for the prevention and treatment of P. gingivalis related conditions and diseases.
US20120114686 COMPOSITIONS AND METHODS RELATED TO PROTEIN A (SPA) VARIANTS  
Disclosed are methods and compositions for treating or preventing a Staphylococcus bacterial infection using a non-toxigenic Protein A (SpA) variant.
US20130189295 COMBINATIONS OF MENINGOCOCCAL FACTOR H BINDING PROTEINS  
The M01573 sequence of meningococcal fHbp offers poor coverage in a vaccine. The invention addresses this poor coverage in two ways. In a first aspect, a fHbp-based vaccine includes two family I...
US20150056240 COMPOSITIONS AND METHODS RELATED TO PROTEIN A (SPA) VARIANTS  
The present invention concerns methods and compositions for treating or preventing a bacterial infection, particularly infection by a Staphylococcus bacterium. The invention provides methods and...
US20130171183 COMPOSITIONS AND METHODS RELATED TO PROTEIN A (SPA) VARIANTS  
The present invention concerns methods and compositions for treating or preventing a bacterial infection, particularly infection by a Staphylococcus bacterium. The invention provides methods and...
US20120121637 CHIMERIC FACTOR H BINDING PROTEINS (FHBP) AND METHODS OF USE  
Chimeric fHbps that can elicit antibodies that are bactericidal for different fHbp variant strains of N. meningitidis, and methods of use, are provided.
US20130071423 COMBINATION VACCINE FOR STREPTOCOCCUS  
The invention relates to the use of a combination of SP1298 and SP2205 proteins or functional fragments thereof or homologous proteins or protein fragments thereof of S. pneumoniae for preventing...
US20110117119 NOVEL COMPOSITIONS AND METHODS  
The present invention is directed to a polypeptide which comprises: (i) an Rv3616c protein sequence; (ii) a variant of an Rv3616c protein sequence; or (iii) an immunogenic fragment of an Rv3616c...
US20110177111 PROTECTIVE VACCINE AGAINST STAPHYLOCOCCUS AUREUS BIOFILMS COMPRISING CELL WALL-ASSOCIATED IMMUNOGENS  
Vaccine formulations effective against Staphylococcus aureus, including methicillin-resistant Staphylococcus aureus (MRSA) are disclosed, as well as methods of using the vaccine formulations in...
US20140314802 NOVEL COMPOSITIONS AND METHODS  
The present invention is directed to a polypeptide which comprises: (i) an Rv2386c protein sequence; (ii) a variant of an Rv2386c protein sequence; of (iii) an immunogenic fragment of an Rv2386c...
US20140178423 NOVEL COMPOSITIONS AND METHODS  
The present invention is directed to a polypeptide which comprises: (i) an Rv2386c protein sequence; (ii) a variant of an Rv2386c protein sequence; or (iii) an immunogenic fragment of an Rv2386c...
US20150209419 ADJUVANTED COMBINATIONS OF MENINGOCOCCAL FACTOR H BINDING PROTEINS  
The M01573 sequence of meningococcal fHbp offers poor coverage in a vaccine. The invention addresses this poor coverage in two ways. In a first aspect, a fHbp-based vaccine includes two family I...
US20120177680 POLYPEPTIDES AND METHODS FOR THE SPECIFIC DETECTION OF ANTIBODIES IN PATIENTS WITH A BORRELIA INFECTION  
The present disclosure relates to proteins derived from OspC from bacteria of the genus Borrelia, in particular a protein which comprises a first OspC polypeptide, wherein the first OspC...
US20150152144 SALMONELLA TYPHI TY21A EXPRESSING YERSINIA PESTIS F1-V FUSION PROTEIN AND USES THEREOF  
Described herein is the generation of a plasmid construct for expression of a Yersinia pestis F1-V fusion protein. In the disclosed plasmid, the F1-V fusion protein coding sequence is operably...
US20140363462 HETEROLOGOUS EXPRESSION OF NEISSERIAL PROTEINS  
Alternative and improved approaches to the heterologous expression of the proteins of Neisseria meningitidis and Neisseria gonorrhoeae are disclosed. These approaches typically affect the level of...
US20140294885 HETEROLOGOUS EXPRESSION OF NEISSERIAL PROTEINS  
Alternative and improved approaches to the heterologous expression of the proteins of Neisseria meningitidis and Neisseria gonorrhoeae are disclosed. These approaches typically affect the level of...
US20150086581 Fast Diagnosis and Personalized Treatment for Acne  
Methods of diagnosing and treating patients afflicted with acne, including diagnosing one as having acne if the individual possesses RT4, RT5, RT7, RT8, RT9, or RT10. Methods for treating acne...
US20150023998 Stable Anthrax Vaccine Formulations  
Formulations of anthrax protective antigen are provided that are stable in storage for prolonged periods. Methods of using the formulations to prepare vaccine are also provided. Vaccines...